This preclinical mouse study found that bone marrow mesenchymal stem cell-derived exosomes (BMSC-exos) reduced deoxynivalenol-induced liver damage by lowering lipid peroxidation markers, inflammatory cytokines, and maintaining liver function, with effects observed in a dose-dependent manner.